Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation

被引：0

作者：

Prelaj, A. ^{[1
]}

Bottiglieri, A. ^{[1
]}

Galli, E. ^{[1
]}

Lo Russo, G. ^{[1
]}

Ferrara, R. ^{[1
]}

Galli, G. ^{[1
]}

De Toma, A. ^{[1
]}

Brambilla, M. ^{[1
]}

Occhipinti, M. ^{[1
]}

Manglaviti, S. ^{[1
]}

Beninato, T. ^{[1
]}

Zattarin, E. ^{[1
]}

Apollonio, G. ^{[1
]}

Ganzinelli, M. ^{[1
]}

Gallucci, R. ^{[1
]}

Di Mauro, R. M. ^{[1
]}

de Braud, F. ^{[1
]}

Torri, V. ^{[2
]}

Garassino, M. C. C. ^{[3
]}

Proto, C. ^{[1
]}

机构：

[1] Ist Nazl Tumori Milano Fdn IRCCS, Med Oncol Dept, Milan, Italy

[2] IRCCS Mario Negri Inst, Dept Oncol, Milan, Italy

[3] Univ Chicago, Dept Hematol Oncol, Chicago, IL 60637 USA

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1841

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1236P

引用

页码：S976 / S977

页数：2

共 50 条

[1] Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
Prelaj, Arsela
Bottiglieri, Achille
Proto, Claudia
Lo Russo, Giuseppe
Signorelli, Diego
Ferrara, Roberto
Galli, Giulia
De Toma, Alessandro
Viscardi, Giuseppe
Brambilla, Marta
Lobefaro, Riccardo
Nichetti, Federico
Manglaviti, Sara
Occhipinti, Mario
Labianca, Alice
Ganzinelli, Monica
Gallucci, Rosaria
Zilembo, Nicoletta
Greco, Gabriella Francesca
Torri, Valter
de Braud, Filippo
Garassino, Marina C.
EUROPEAN JOURNAL OF CANCER, 2021, 149 : 235 - 248
[2] Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib
不详
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program
Prelaj, A.
Bottiglieri, A.
Proto, C.
Lo Russo, G.
Signorelli, D.
Ferrara, R.
Galli, G.
De Toma, A.
Viscardi, G.
Brambilla, M.
Lobefaro, R.
Manglaviti, S.
Occhipinti, M.
Labianca, A.
Gallucci, R.
Molino, G.
Zilembo, N.
Greco, F. G.
Torri, V.
Garassino, M. C.
ANNALS OF ONCOLOGY, 2020, 31 : S882 - S882
[4] Development of treatment for HER2 or EGFR exon 20 insertion mutation-driven NSCLC
Ninomiya, Kiichiro
ANNALS OF ONCOLOGY, 2022, 33 : S444 - S444
[5] First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate
Prelaj, A.
Bottiglieri, A.
Lo Russo, G.
Ferrara, R.
Galli, G.
De Toma, A.
Brambilla, M.
Occhipinti, M.
Manglaviti, S.
Beninato, T.
Zattarin, E.
Apollonio, G.
Massa, G.
Mazzeo, L.
Galli, E.
Dumitrascu, D.
Ganzinelli, M.
Gallucci, R.
Di Mauro, R.
Vitale, S.
De Braud, F. G. M.
Garassino, M. C.
Proto, C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1116 - S1117
[6] Clinical outcomes for EGFR/HER2 exon 20 insertion-mutated NSCLC
Li, K.
Bosdet, I.
Yip, S.
Ho, C.
Laskin, J.
Melosky, B.
Wang, Y.
Sun, S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1058 - S1059
[7] ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
Socinski, M. A.
Cornelissen, R.
Garassino, M. C.
Clarke, J.
Tchekmedyian, N.
Molina, J.
Goldman, J. W.
Bhat, G.
Lebel, F.
Le, X.
ANNALS OF ONCOLOGY, 2020, 31 : S1188 - S1188
[8] Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients
Cornelissen, R.
Garassino, M. C.
Le, X.
Clarke, J.
Tchekmedyian, N.
Goldman, J.
Lebel, F.
Bhat, G.
Socinski, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S173 - S174
[9] Efficacy of poziotinib in HER2 exon 20 insertion NSCLC patients who received prior platinum-based and HER2 targeted therapies
Prelaj, A.
Le, X.
Proto, C.
Baik, C. S.
Tchekmedyian, N.
Heymach, J.
Bhat, G.
Cornelissen, R.
ANNALS OF ONCOLOGY, 2023, 34
[10] Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib
Yang, Juyin
Yang, Jian
Ban, Shao
Li, Xinmin
Chen, Xingde
Yang, Jihua
Qian, Jun
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : E198 - E200

← 1 2 3 4 5 →